课题基金 / 基金详情

Therapeutic Targeting of The Long Noncoding RNA SCHLAP1 in Aggressive Prostate Cancer

Therapeutic Targeting of The Long Noncoding RNA SCHLAP1 in Aggressive Prostate Cancer
长非编码 RNA SCHLAP1 在侵袭性前列腺癌中的治疗靶向
批准号:
10577329
负责人:
Amanda E Hargrove
金额:
$22.22万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
已结题
起止时间:
2023-01-12 至 2024-12-31

项目摘要

项目成果

Amanda E Hargrove的其他基金

相似基金

相关文献

中文摘要
翻译
前列腺癌(PCa)是美国男性死亡的主要原因。几乎所有这些死亡都是由于 治疗抗性和转移扩散的演变。因此,迫切需要开发新的药剂, 治疗耐药的转移性前列腺癌长链非编码RNA(lncRNA)第二染色体位点相关 与前列腺1(SChLAP 1)已被确定为与前列腺癌特异性死亡率相关的顶级RNA, 来自多个数据集的转移与长期随访。SChLAP 1的敲低/过表达与 伴随促转移表型的改变,如侵袭和集落形成。瞄准这个关键的细胞 然而,调节剂一直是难以捉摸的,其在促进PCa治疗抗性和转移中的作用机制 尚未完全阐明。例如,SChLAP 1和SWI/SNF复合物之间的相互作用已经被证实。 在一些研究中与PCa进展有关,但在其他研究中则无此发现。在分子水平上的知识空白 SChLAP 1的功能阻止SChLAP 1的有效治疗靶向。我们团队和其他人最近的工作 揭示了SChLAP 1内复杂的RNA结构以及定位于高度结构化的蛋白质结合区域, 和转录物的灵长类保守区域。这一令人信服的证据表明,功能性RNA结构,结合 随着SChLAP 1作为尿液和血液中的生物标志物的可用性,使得靶向lncRNA SChLAP 1成为一种有希望的方法。 针对侵袭性前列腺癌男性的精准药物治疗方法。 拟议工作的总体目标是:1)识别和表征蛋白质相互作用物, 对SChLAP 1致癌活性至关重要的染色质结合位点和2)验证最近鉴定的药物样配体 筛选作为靶向SChLAP 1结构化区域的工具分子,包括抑制这些相互作用, SChLAP 1驱动的表型。中心假设是SChLAP 1的机制涉及与 蛋白质和染色质,靶向这些相互作用将抑制SChLAP 1驱动的表型,并揭示 治疗转移性、耐药前列腺癌的新的治疗途径。在目标1中,无偏测序和质量 基于光谱的方法将鉴定细胞中SChLAP 1结合的染色质区域和蛋白质, 将在一系列表型测定中研究它们之间的相互作用,以评价它们在增殖、癌细胞增殖、肿瘤细胞增殖和肿瘤细胞增殖中的作用。 存活、迁移/侵袭和对标准治疗激素疗法的抗性。在目标2中,保守的配体 SChLAP 1亚结构将在表型测定中得到验证,它们对分子相互作用的影响将在 审问。这项工作的预期成果将如下:1)全面的生物学见解, SChLAP 1的分子间相互作用和2)抑制SChLAP 1的小分子的鉴定:蛋白质 相互作用和随后的表型。这项工作将为未来的R 01提案奠定基础, 靶向SChLAP 1的小分子的体内验证研究和基于外泌体的液体的开发 SChLAP 1的活检,最终目标是产生一种精确的基于医学的策略, 治疗抗性PCa,同时也有助于建立lncRNA靶向作为肿瘤学中的治疗范例。
英文摘要
Prostate cancer (PCa) is a leading cause of death among American men. Nearly all of these deaths are due to the evolution of therapy resistance and metastatic spread. As such, there is an urgent, unmet need to develop new agents to treat therapy-resistant, metastatic PCa. The long noncoding RNA (lncRNA) Second Chromosome Locus Associated with Prostate 1 (SChLAP1) has been identified as the top RNA associated with prostate cancer-specific mortality and metastasis from multiple datasets with long-term follow up. Knockdown/overexpression of SChLAP1 is associated with changes to pro-metastatic phenotypes, such as invasion and colony formation. Targeting this critical cellular regulator has been elusive, however, and its mechanism of action in promoting PCa therapy resistance and metastasis has not been fully elucidated. For example, an interaction between SChLAP1 and the SWI/SNF complex has been implicated in PCa progression in some studies, but not in others. This gap in knowledge regarding the molecular function of SChLAP1 prevents effective therapeutic targeting of SChLAP1. Recent work by our team and others has revealed a complex RNA architecture within SChLAP1 as well as protein binding regions localized to highly structured and primate-conserved regions of the transcript. This compelling evidence for functional RNA structures, combined with the availability of SChLAP1 as a biomarker in urine and blood, renders targeting of lncRNA SChLAP1 a promising precision medicine-based treatment approach for men with aggressive PCa. The overall objectives of the proposed work are to: 1) identify and characterize protein interactors and chromatin-binding sites critical to SChLAP1 oncogenic activity and 2) validate drug-like ligands identified in recent screens as tool molecules for targeting structured regions of SChLAP1, including inhibition of these interactions and SChLAP1-driven phenotypes. The central hypothesis is that the mechanism of SChLAP1 involves interactions with both protein and chromatin, and that targeting these interactions will inhibit SChLAP1-driven phenotypes and reveal novel therapeutic avenues to treat metastatic, treatment-resistant PCa. In Aim 1, unbiased sequencing and mass spectrometry-based approaches will identify chromatin regions and proteins bound by SChLAP1 in cells, and these interactions will be interrogated in an array of phenotypic assays to evaluate their role in proliferation, cancer cell survival, migration/invasion, and resistance to standard-of-care hormone therapy. In Aim 2, ligands of conserved SChLAP1 substructures will be validated in phenotypic assays, and their effects on molecular interactions will be interrogated. Expected outcomes of this work will be as follows: 1) comprehensive biological insight into targetable intermolecular interactions for SChLAP1 and 2) identification of small molecules that inhibit SChLAP1:protein interactions and subsequent phenotypes in PCa. This work will set the stage for a future R01 proposal focused on in vivo validation studies for small molecules targeting SChLAP1 and the development of an exosome-based liquid biopsy for SChLAP1, with the ultimate goal of yielding a precision medicine-based strategy for aggressive and treatment-resistant PCa while also helping to establish lncRNA targeting as a therapeutic paradigm in oncology.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Harnessing Small Molecules to Probe the Structure and Function of Long Noncoding RNAs
  • 批准号:
    9381663
  • 项目类别:
  • 资助金额:
    $38.06万
  • 财政年份:
    2017
  • 负责人:
    Amanda E Hargrove
  • 依托单位:
Harnessing Small Molecules to Probe the Structure and Function of Long Noncoding RNAs
  • 批准号:
    10220988
  • 项目类别:
  • 资助金额:
    $38.06万
  • 财政年份:
    2017
  • 负责人:
    Amanda E Hargrove
  • 依托单位:
Harnessing Small Molecules to Probe the Structure and Function of Regulatory RNAs
  • 批准号:
    10405219
  • 项目类别:
  • 资助金额:
    $42.53万
  • 财政年份:
    2017
  • 负责人:
    Amanda E Hargrove
  • 依托单位:
Harnessing Small Molecules to Probe the Structure and Function of Long Noncoding RNAs
  • 批准号:
    10001564
  • 项目类别:
  • 资助金额:
    $38.06万
  • 财政年份:
    2017
  • 负责人:
    Amanda E Hargrove
  • 依托单位:
海外基金